FY2025 EPS Estimates for Alkermes Boosted by Zacks Research

Alkermes plc (NASDAQ:ALKS) – Investment analysts at Zacks Research increased their FY2025 EPS estimates for shares of Alkermes in a report released on Tuesday, November 18th. Zacks Research analyst Team now forecasts that the company will post earnings of $1.71 per share for the year, up from their prior estimate of $1.49. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share.

A number of other analysts have also commented on ALKS. Piper Sandler reissued an “overweight” rating and set a $45.00 price objective (up from $38.00) on shares of Alkermes in a report on Thursday, October 23rd. Wells Fargo & Company cut their target price on Alkermes from $42.00 to $37.00 and set an “overweight” rating on the stock in a research report on Thursday, November 13th. Mizuho increased their price target on Alkermes from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Monday, October 27th. JPMorgan Chase & Co. raised their price objective on Alkermes from $34.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, September 9th. Finally, Truist Financial upped their target price on shares of Alkermes from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.69.

Alkermes Price Performance

ALKS opened at $28.61 on Friday. Alkermes has a fifty-two week low of $25.17 and a fifty-two week high of $36.45. The firm has a market capitalization of $4.72 billion, a PE ratio of 14.16, a P/E/G ratio of 1.70 and a beta of 0.53. The company’s 50-day moving average is $30.14 and its 200 day moving average is $29.48.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.08. The firm had revenue of $394.19 million for the quarter, compared to analyst estimates of $355.23 million. Alkermes had a net margin of 22.27% and a return on equity of 21.81%. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period last year, the firm earned $0.73 earnings per share. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ALKS. Cerity Partners LLC raised its holdings in shares of Alkermes by 46.3% in the 1st quarter. Cerity Partners LLC now owns 26,240 shares of the company’s stock worth $866,000 after purchasing an additional 8,310 shares during the period. Victory Capital Management Inc. increased its position in Alkermes by 30.9% in the first quarter. Victory Capital Management Inc. now owns 120,997 shares of the company’s stock worth $3,995,000 after buying an additional 28,596 shares during the last quarter. Y Intercept Hong Kong Ltd raised its stake in shares of Alkermes by 76.3% in the first quarter. Y Intercept Hong Kong Ltd now owns 25,339 shares of the company’s stock valued at $837,000 after buying an additional 10,966 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH lifted its position in shares of Alkermes by 22.4% during the 1st quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 139,311 shares of the company’s stock valued at $4,600,000 after buying an additional 25,493 shares during the last quarter. Finally, Avantax Advisory Services Inc. purchased a new position in shares of Alkermes during the 1st quarter valued at $246,000. 95.21% of the stock is owned by institutional investors.

Insider Buying and Selling at Alkermes

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $30.38, for a total transaction of $273,420.00. Following the completion of the sale, the executive vice president owned 69,740 shares in the company, valued at approximately $2,118,701.20. This trade represents a 11.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.40% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.